bioRxiv Science⌕ Search

Biology subjects

Bordeleau, M.-E.

Publications and source records attributed to Bordeleau, M.-E..

2 recordsLinked to original sources

SPAT: Surface Protein Annotation Tool

Given the particular attractivity of antibody-based immunotherapies, in vitro experimental approaches aiming to identify and quantify proteins directly located at the cell surface, such as the surfaceome, have been recently developed and improved. However, the "surface" enriched, yet noisy output obtained from available methods makes it challenging to accurately evaluate which proteins are more likely to be located at the surface of the plasma membrane and which are simple contaminants. To that purpose, we developed the in silico Surface Protein Annotation Tool (SPAT), which unifies established annotations to grade proteins according to the chance they have to be located at the cell surface. SPAT accuracy was tested using in-house acute myeloid leukemia data, as well as public datasets, and despite using publicly available annotations, showed good performances when compared to more complex surfaceome predictors. Given its simple input requirement, SPAT is easily usable for the annotation of any gene/protein lists. Its output, in addition to the "surface" score, provides additional annotations including a "secretion" flag, references to verified antibodies targeting annotated proteins, as well as expression data and protein levels in essential human organs, making it a user-friendly tool for the community.

bioinformatics↗

Genetic Landscape of Electron Transport Chain Complex I Dependency in Acute Myeloid Leukemia

Inhibition of oxidative phosphorylation (OXPHOS) is a promising therapeutic strategy in Acute Myeloid Leukemia (AML), but patients respond heterogeneously. Through chemically interrogation of 200 sequenced specimens, we identified Mubritinib as a strong in vitro and in vivo anti-leukemic compound, acting through ubiquinone-dependent inhibition of Electron Transport Chain complex I (ETC1). ETC1 targeting showed selective toxicity against a subgroup of chemotherapy-resistant leukemias exhibiting OXPHOS hyperactivity, high expression of mitochondrial activity-related genes, and mutations affecting NPM1, FLT3 and DNMT3A. Altogether, our work thus identifies a novel ETC1 inhibitor with high clinical potential and reveals the landscape of OXPHOS dependency in AML.

cancer biology↗